EARLY DISEASE CLEARANCE WITH ETRASIMOD AND CORRELATION WITH WEEK 52 OUTCOMES AND BIOMARKERS: A POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC TRIALS

Fernando Magro  ¹     Laurent Peyrin-Biroulet  ^{2, 3}     Bruce E. Sands  ⁴     Silvio Danese  ⁵     Vipul Jairath  ⁶     Martina Goestch  ⁷     Abhishek Bhattacharjee  ⁸     Joseph Wu  ⁹     Diogo Branquinho  ¹⁰     Irene Modesto  ¹¹     Brian G. Feagan  ^{6, 12    
1} University of Porto and Centro Hospitalar São João, Porto, Portugal
² University of Lorraine, CHRU-Nancy, Nancy, France
³ University of Lorraine, Inserm, NGERE, Nancy, France
⁴ Icahn School of Medicine at Mount Sinai, New York, United States
⁵ IRCCS San Raffaele Hospital and Vita Salute San Raffaele University, Milan, Italy
⁶ Western University, London, Canada
⁷ Pfizer AG, Zürich, Switzerland
⁸ Pfizer Healthcare India Pvt. Ltd, Chennai, India
⁹ Pfizer Inc, Groton, United States
¹⁰ Pfizer Inc, New York, United States
¹¹ Pfizer Inc, Madrid, Spain
¹² Alimentiv Inc, London, Canada

Topic
IBD

Session
Traffic control in IBD

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)